Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00094159 · ClinicalTrials.gov registry record · Phase 1

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

A Phase 1 study, sponsored by Sunesis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase

NCT00094159: Completed Phase 1 study, sponsored by Sunesis Pharmaceuticals.

NCT00094159 is a Phase 1 study that has completed, run by Sunesis Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00094159, a Phase 1 study, has completed, sponsored by Sunesis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.

Interventions

  • DRUG SNS-595

Trial Details

FieldValue
Start Date 2004-10
Phase Phase 1
Sunesis Pharmaceuticals

13 total trials

What the finished NCT00094159 record still lists

NCT00094159 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which SNS-595 is the first listed.

NCT00094159 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00094159 about?

NCT00094159 is a clinical study titled "Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors". The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.

What is the current status of trial NCT00094159?

This trial is currently completed. It is a Phase 1 study. The study started on 2004-10.

What interventions are being tested in trial NCT00094159?

The interventions under investigation include: SNS-595 (DRUG).

Who is sponsoring clinical trial NCT00094159?

This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00094159, the US trial registry maintained by the National Library of Medicine. NCT00094159 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.